Unsubscribe
To unsubscribe from communications about SUBLOCADE, please enter your email address below.
INDICATION: SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII, is for adults with moderate to severe opioid addiction whose withdrawal symptoms are controlled by oral buprenorphine for at least 7 days. READ MORE FOR FULL INDICATION
INDICATION: SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII, is a prescription medicine used to treat adults with moderate to severe addiction (dependence) to opioid drugs (prescription or illegal) who have received an oral transmucosal (used under the tongue or inside the cheek) buprenorphine-containing medicine at a dose that controls withdrawal symptoms for at least 7 days. SUBLOCADE is part of a complete treatment plan that should include counseling.
To unsubscribe from communications about SUBLOCADE, please enter your email address below.
Because of the serious risk of potential harm or death from self-injecting SUBLOCADE into a vein (intravenously), it is only available through a restricted program called the SUBLOCADE REMS Program.
SUBLOCADE contains a medicine called buprenorphine. Buprenorphine is an opioid that can cause serious and life‑threatening breathing problems, especially if you take or use certain other medicines or drugs.
Talk to your healthcare provider about naloxone. Naloxone is a medicine that is available to patients for the emergency treatment of an opioid overdose. If naloxone is given, you must call 911 or get emergency medical help right away to treat overdose or accidental use of an opioid.
SUBLOCADE may cause serious and life‑threatening breathing problems. Get emergency help right away if you:
Do not take certain medicines during treatment with SUBLOCADE. Taking other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) while on SUBLOCADE can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.
In an emergency, have family members tell emergency department staff that you are physically dependent on an opioid and are being treated with SUBLOCADE.
You may have detectable levels of SUBLOCADE in your body for a long period after stopping treatment with SUBLOCADE.
Death has been reported in those who are not opioid dependent who received buprenorphine sublingually.
Who should not take SUBLOCADE?
Do not use SUBLOCADE if you are allergic to buprenorphine or any ingredient in the prefilled syringe (Indivior’s proprietary buprenorphine gel depot delivery system, a biodegradable 50:50 poly(DL-lactide-co-glycolide) polymer and a biocompatible solvent, N-methyl-2-pyrrolidone (NMP)).
Before starting SUBLOCADE, tell your healthcare provider about all of your medical conditions, including if you have:
Tell your healthcare provider if you are:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
SUBLOCADE can cause serious side effects, including:
These are not all the possible side effects. Call your healthcare provider for medical advice about side effects.
To report a pregnancy or side effects associated with taking SUBLOCADE or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966. You are encouraged to report negative side effects of drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information, including BOXED WARNING, and Medication Guide. For REMS information visit www.sublocadeREMS.com.